Search results for: Generics
Filter search results
OHE Develops New, Bottom-Up Model for Forecasting UK Medicines Expenditure
3 April 2013
…the market or the appearance of generics. Most projections of medicines spending are rooted in the past and are “top-down”, macro-based approaches. Such models are based on econometric analyses of…
Price Competition and Biosimilars
23 June 2010
Virtually all models forecast that price competition will be less intense and price declines modest in comparison to the generics model. Many models, however, miss or underestimate factors and trends…
Estimating US Savings from Biosimilars
13 July 2010
…growth hormone or rheumatoid arthritis products. In addition, a key driver of market penetration for small-molecule generics, the pharmacist, will have far less impact on biologics, both because of current…
Published: OHE Study Projecting UK Medicines Expenditure
30 September 2013
…new generics and biosimilars. In a comparison of results, the bottom-up approach was shown to provide richer detail about causes and distribution of costs, i.e. which therapeutic areas may consume…
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
…for generics and biosimilars. Accounting for all these benefits from generic/biosimilar competition in the UP scenario (and for a 100-year time horizon) is unrealistic. The modelling contains naïve assumptions about…
Drug shortages are on the rise – but what is their impact?
16 September 2024
…consideration must be given to the downstream impact this may cause to vulnerable supply chains and higher risks of shortages, particularly in the generics and biosimilars market which already only…
Dr. Sabine Vogler
4 September 2024
…Open, of the Generics and Biosimilars Initiative (GaBI) journal and of the International Advisory Board of the Pharmaceutical Policy and Practice (JOPPP) journal as well as an Associate Editor of…
Biosimilars: Modelling the Evolution of the Market
16 June 2010
…of Prof Adrian Towse and Dr Jorge Mestre-Ferrandiz. Describing and/or forecasting the market for biosimilars must first recognize that these products are not identical, i.e., not ‘biogenerics.’ This affects both…
Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges
6 February 2023
…drugs at prices close to those of generics, facilitating greater patient access and placing less strain on budgets. Additional reward payments would then be made over the course of a…